振德醫療(603301.SH)擬投建生產基地及醫用生物新材料研究院項目
格隆匯2月9日丨振德醫療(603301.SH)公佈,根據公司戰略發展和業務發展需要,結合公司經營現狀,為進一步拓展公司產品和業務佈局,提升公司研發創新和核心技術能力,公司擬在浙江省紹興濱海新區以公開競買方式取得國有建設用地使用權(土地面積預計約100畝),投資建設新型防護用品、手術通路類醫療器械生產基地及醫用生物新材料研究院建設項目,項目總投資合計約6.5億元。
公司計劃在取得項目建設用地後建設生產車間、物流倉儲及研發辦公用房等建構築物約13萬平方米。建構築物建設完成後,公司將配置行業領先的新型防護用品、手術通路類醫療器械生產設備和醫用生物新材料研究院研發設備,並配套輔助生產系統。
項目實施完成並達產後,將整體形成4000萬件新型防護用品(銅基沸石紗布口罩等防護用品)、240萬件手術通路類醫療器械(一次性使用穿刺器等)的生產能力;同時建設的醫用生物新材料研究院將主要從事新材料基礎研究、應用研究以及技術平台建立,在醫用生物材料、醫用高分子材料、皮膚界面粘合材料、醫用防護材料、感控材料和技術等方面,建立團隊和先進實驗室。
項目總投資約6.5億元,其中土地費、建築安裝及工程其他費用合計約4.2億元,新型防護用品生產設備購置費4700萬元,手術通路類醫療器械生產設備購置費8300萬元,研發設備購置費6000萬元,流動資金約4000萬元。經公司初步測算,本次投資項目財務內部收益率為15.55%,投資回收期為4.77年(不含建設期)。項目建設期約為36個月。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.